News For QGEN From The Last 14 Days Check below for free stories on QGEN the last two weeks.
There are 6 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 9, 2010
|
| 12:26 EDT |  | QGEN |
|
|
February 8, 2010
|
| 16:12 EDT |  | QGEN |
| theflyonthewall.com: | Qiagen sees FY10 revenue $1.12B-$1.17B vs. consensus of $1.16B | | :theflyonthewall.com |
| | 16:10 EDT | | QGEN |
| | 16:09 EDT |  | QGEN |
| theflyonthewall.com: | Qiagen acquires exclusive license for key PI3K gene | | Qiagen announced that its wholly owned subsidiary DxS has acquired the global and exclusive licence for biomarker PI3K from Johns Hopkins University to develop real-time-PCR and endpoint PCR assays. Research has shown that variation in the PI3K gene could be a key biomarker for use as a companion diagnostic with certain cancer treatments. The studies suggest that mutations in the PI3K oncogene are predictive for the success of certain treatments of patients suffering from lung, breast, colorectal and other cancers. QIAGEN has an active PI3K assay development and partnering program with pharmaceutical companies to develop and market tests for new cancer drug candidates. Financial details were not disclosed. :theflyonthewall.com |
| | 09:17 EDT |  | QGEN |
|
|
February 4, 2010
|
| 16:02 EDT | | QGEN |
| theflyonthewall.com: | Pfizer enters agreement with Qiagen | | Pfizer (PFE) and DxS, a wholly owned subsidiary of Qiagen (QGEN) announced that they have entered into an agreement to develop a companion diagnostic test kit for PF-04948568 (CDX-110), an immunotherapy vaccine in development for the treatment of glioblastoma multiforme. Financial terms of the diagnostic agreement have not been disclosed. :theflyonthewall.com |
|
|
|
Subscribe for More Information